Supportive care and palliation in patients with malignant gliomas;Supportive therapie und palliativmedizin bei patienten mit malignen gliomen

Wiener Medizinische Wochenschrift

Volumn 156, Issue 11-12, 2006, Pages 364-368

  Oberndorfer, Stefan ^a,b   Lahrmann, Heinz ^a  

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Malignant glioma; Palliation; Supportive care

Indexed keywords

ANTIDEPRESSANT AGENT; DEXAMETHASONE; MANNITOL; PHENYTOIN;

CANCER PALLIATIVE THERAPY; CLINICAL FEATURE; DEPRESSION; EPILEPSY; FATIGUE; GLIOBLASTOMA; HUMAN; NEURORADIOLOGY; PATIENT CARE; QUALITY OF LIFE; REVIEW; SYMPTOMATOLOGY;

BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; GLIOMA; HUMANS; PALLIATIVE CARE; PATIENT CARE TEAM; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 33746834558     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10354-006-0309-2     Document Type: Review

References (41)

1. Davies E, Clarke C (2005) Views of bereaved relatives about quality of survival after radiotherapy for malignant cerebral glioma. J Neurol Neurosurg Psychiatry 76: 555-561
2. de Wit MC, de Bruin HG, Eijkenboom W, Sillevis Smitt PA, van den Bent MJ (2004) Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 63: 535-537
3. Laigle F, Martin-Duverneuil N, Carpentier A, Hoang-Xuan K, Delattre JY (2002) Seizure-related contrast enhancement of a ganglioglioma. Neurology 58: 1538
4. Kawahara I, Tsutsumi K, Hirose M, Matsuo Y, Yokoyama H (2004) Transient abnormalities associated with status epilepticus on diffusion-weighted MR imaging. No To Shinkei 56: 333-338
5. Lansberg MG, O'Brien MW, Norbash AM, Moseley ME, Morrell M, Albers GW (1999) MRI abnormalities associated with partial status epilepticus. Neurology 52: 1021-1027
6. Kim JA, Chung JI, Yoon PH, Kim DI, Chung TS, Kim EJ, Jeong EK (2001) Transient MR signal changes in patients with generalized tonicoclonic seizure or status epilepticus: periictal diffusion-weighted imaging. AJNR Am J Neuroradiol 22: 1149-1160
7. Oberndorfer S, Lindeck-Pozza E, Lahrmann L, Struhal W, Hitzenberger H, Grisold W (2006) The "end of life" hospital setting in patients with malignant gliomas. Neurooncol (submitted)
8. Peterson K (2004) Neoplasms. In: Voltz R, Bernat LL et al (eds) Palliative Care in Neurology. Contemporary neurology series. Oxford University Press, Oxford, Chapter 4, pp 37-47
9. Giovagnoli AR, Silvani A, Colombo E, Boiardi A (2005) Facets and determinants of quality of life in patients with recurrent high grade glioma. J Neurol Neurosurg Psychiatry 76: 562-568
10. Massie MJ, Holland JC, Glass E (1989) Overview of normal reaction and praevalence of psychiatric disorder. In: Holland JC, Rowland JH (eds) Handbook of psychooncology. Psychological care of the patient with cancer. Oxford University Press, New York, pp 273-282
11. Cherny NI, Coyle N, Foley KM (1994) Suffering in the advanced cancer patient: a definition and taxonomy. J Palliat Care 10: 57-70
12. Posner JB (1995) Neurological complications in cancer. FA Davis Company, Philadelphia, pp 59-66
13. Hildebrand J, Brada M (2001) Brain oedema. In: Differential Diagnosis in Neuro-oncology. Oxford University Press, New York, pp 47-58
14. Das A, Banik NL, Patel SJ, Ray SK (2004) Dexamethasone protected human glioblastoma U87MG cells from temozolomide induced apoptosis by maintaining Bax:Bcl-2 ratio and preventing proteolytic activities. Mol Cancer 3: 36
15. Sur P, Sribnick EA, Patel SJ, Ray SK, Banik NL (2005) Dexamethasone decreases temozolomide-induced apoptosis in human gliobastoma T98G cells. Glia 50: 160-167
16. Hermisson M, Klumpp A, Wick W, Wischhusen J, Nagel G, Roos W, Kaina B, Weller M (2006) O-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem 96(3): 766-776
17. U Schlegel (?) Klinische Symptomatik und allgemeine Terapie. In: Schlegel U, Weller M, Westphal M (Hrsg) Neuroonkologie. Georg Thieme, Stuttgart New York, pp 84-92
18. Oberndorfer S, Schmal T, Lahrmann H, Urbanits S, Lindner K, Grisold W (2002) [The frequency of seizures in patients with primary brain tumors or cerebral metastases. Wien Klin Wochenschr 114 (21-22): 911-916
19. Cobbs JL, Lekos A, Cole BF, Recht L, Mills PC, Akerley W, Glantz MJ (1997) Natural history of seizures and the role of anticonvulsants in patients with primary and metastatic central nervous system cancer. Neurology 48: A19 (abstract)
20. Oberndorfer S, Piribauer M, Marosi Ch, Lahrmann H, Hitzenberger P, Grisold W (2005) P450 enzyme inducing and non enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J Neurooncol 72(3): 255-260
21. Forsyth PA, Posner JB (1993) Headaches in patients with brain tumors: a study of 111 patients. Neurology 43: 1678-1683
22. Siraj M Husain, et al (2003) Headache associated with intracranial neoplasms. In: Schiff D, Wen PY (eds) Cancer Neurology in Clinical Practice. Humana Press, Totowa, New Jersey, pp 23-39
23. Pfund Z, Szapary L, Jaszberenyi O, Nagy F, Czopf J (1999) Headache in intracranial tumors. Cephalalgia 19:787-790; discussion 765
24. Purdy RA, Kirby S (2004) Headaches and brain tumors. Neurol Clin 22:39-53
25. Hess B, Oberndorfer S, Urbanits S, Lahrmann H, Horvath-Mechtler B, Grisold W (2005) Trigeminal neuralgia in two patients with glioblastoma. Headache 45: 1267-1270
26. Cummings J (1985) Behavioral disorders associated with frontal lobe injury. In: Clinical neuropsychiatry. Grune Stratton, Orlando, pp 57-74
27. Hahn CA, Dunn RH, Logue PE, King JH, Edwards CL, Halperin EC (2003) Prospective study of neuropsychologic testing and quality-of-life assessment of adults with primary malignant brain tumors. Int J Radiat Oncol Biol Phys 55: 992-999
28. Madhusoodanan S, Danan D, Brenner R, Bogunovic O (2004) Brain tumor and psychiatric manifestations: a case report and brief review. Ann Clin Psychiatry 16: 111-113
29. Meyers CA, Hess KR, Yung WK, Levin VA (2000) Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J Clin Oncol 18: 646-650
30. McDaniel JS, Musselman DL, Porter MR, Reed DA, Nemeroff CB (1995) Depression in patients with cancer. Diagnosis, biology, and treatment. Arch Gen Psychiatry 52: 89-99
31. Klein M, Taphoorn MJ, Heimans JJ, van der Ploeg HM, Vandertop WP, Smit EF, Leenstra S et al. (2002) Neurobehavioral status and health-related quality of life in newly diagnosed high-grade glioma patients. Curr Neurol Neurosci Rep 2: 203-204
32. John G, Eapen V, Shaw GK (1997) Frontal glioma presenting as anxiety and obsessions: a case report. Acta Neurol Scand 96: 194-195
33. Moise D, Madhusoodanan S (2006) Psychiatric symptoms associated with brain tumors: a clinical enigma. CNS Spectr 11: 28-31
34. Berney A, Stiefel F, Mazzocato C, Buclin T (2000) Psychopharmacology in supportive care of cancer: a review for the clinician. III. Antidepressants. Support Care Cancer 8: 278-286
35. Schmidinger M, Linzmayer L, Becherer A, Fazeny-Doemer B, Fakhrai N, Prayer D, Killer M et al. (2003) Psychometric-and quality-of-life assessment in long-term glioblastoma survivors. J Neurooncol 63: 55-61
36. Lovely MP, Miaskowski C, Dodd M (1999) Relationship between fatigue and quality of life in patients with glioblastoma multiforme. Oncol Nurs Forum 26: 921-925
37. Wagner LI, Cella D, Doninger NA (2004) Fatigue. In: Voltz R, Bernat LL et al (eds) Palliative Care in Neurology. Contemporary neurology series. Oxford University Press, Oxford, Chapter 21, pp 221-227
38. Mendoza TR, Wang XS, Cleeland CS, Morrissey M, Johnson BA, Wendt JK, Huber SL (1999) The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer 85: 1186-1196
39. Cheruku R, Tapazoglou E, Ensley J, Kish JA, Cummings GD, al-Sarraf M (1991) The incidence and significance of thromboembolic complications in patients with high-grade gliomas. Cancer 68: 2621-2624
40. Sawaya R, Highsmith RF (1992) Postoperative venous thromboembolism and brain tumors: Part III. Biochemical profile. J Neurooncol 14: 113-118
41. Willis BK (1991) Timing of anticoagulant therapy for thromboembolic complications after craniotomy for brain tumors. Neurosurgery 28: 929-930